Document is current

Article History

Received: 2 April 2024

Accepted: 17 March 2025

First Online: 10 April 2025

Declarations

:

: The study protocol, informed consent forms, and information for patients were approved by the Ethical and Clinical Research Committee of Principado de Asturias. Also, the study was conducted according to the guidelines of the Spanish Agency of Medicines and Medical Devices, with the post-marketing study code NOV-EMS-2019-01. Before being included in the study, participants were required to provide informed consent.

: No individual data included in the manuscript.

: COG has received speaker and consultation fees from: Alexion, Biogen Idec, Bristol-Myers-Squibb, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva. JEML has received grants or contracts from: Sanofi, Biogen, Novartis, Roche, Bristol Myers Squibb, Merck, Janssen, and Alexion; consulting fees from: Biogen, Sanofi, Bristol Myers Squibb, Merck, Janssen, and Alexion; payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events and Support for attending meetings and/or travel from: Sanofi, Biogen, Novartis, Roche, Bristol Myers Squibb, Merck, and Janssen. MAHP has received payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events and support for attending meetings and/or travel from: Biogen, Merck, Novartis, and Sanofi. JGG has received payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from: Biogen, Merck, Sanofi, Roche, Teva, Janssen, and Novartis; payment for expert testimony from: Roche, and Sanofi; support for attending meetings and/or travel from: Biogen, Merck, Sanofi, Roche, Teva, Janssen, Almirall, and Novartis; participation on a Data Safety Monitoring Board or Advisory Board: Sanofi. AMAT has received consulting fees from: Novartis, Biogen, Janssen, Roche, and Sanofi; payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from: Merck, Sanofi, Janssen, Almirall, Roche, Novartis, Biogen, and BMS; support for attending meetings and/or travel: Biogen. BPF has received speaker honoraria from: Novartis and Almirall; travel honoraria from: Merck and Sanofi; training honoraria from: Sanofi and Merck. LRT has received consulting fees from: BMS and Sanofi; payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from: BMS, Sanofi, Novartis, Merck, Janssen, Biogen, and Horizon; support for attending meetings and/or travel from: BMS, Sanofi, Novartis, Merck, Janssen, and Biogen. SEM has received speaker honoraria and consultant fees from: Janssen, Bristol-Meyers-Squibb, Biogen Idec, Novartis, Merck, Bayer, Sanofi Genzyme, Roche, and Teva. FGG has received funding for research grants, travel support and honoraria for speaking engagements from: Bayer, Biogen, Roche, Merck, Novartis, Almirall, Teva, Bristol-Meyers-Squibb, and Genzyme-Sanofi. BC has received grants for advisory boards from: Sanofi, Roche, Merck, Horizon, and Novartis. SMY has participated as Principal Investigator in clinical trials promoted by industry from: Roche, Sanofi, Biogen, Merck, and Novartis; support for attending meetings and/or travel from: Biogen, BMS, Janssen, Merck, Novartis, Roche, and Sanofi. MAV has been consulting for: Novartis, Biogen, Sanofi, and Merck; payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from: Novartis, Biogen, Sanofi, Merck, and Roche. Grants or contracts from: Novartis, Biogen, Sanofi, Merck, and Teva; support for attending meetings and/or travel from: Novartis, Biogen, Sanofi, Merck, Teva, and Roche. MLMG has received compensation for consulting services and speaking fees from: Merck, Biogen, Novartis, Sanofi, Almirall, Roche, BMS, Janssen-Cilag, and Viatris. YEBM has received payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from: Novartis, Roche, Sanofi-Genzyme, Almirall, Bayer, Merck, and Biogen. AMLR has acted as a speaker for Roche, Biogen Idec, Genzyme-Sanofi, Janssen, and Novartis. JEMR has participated as consultant and has received payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from: Novartis, Biogen Idec, Sanofi, and Merck Serono. LCF has received honoraria for lecturing, travel expenses for attending meetings from: Merck, Bayer, Biogen, Novartis, Sanofi Genzyme, Almirall, Roche, Celgene, Biopas, Ipsen, and Teva. MGR has received honoraria as a lecturer from: Sanofi-Aventis, Novartis, Biogen, and Merck. TCT has received speaking/consulting fees and/or travel funding from: Almirall, Biogen, Bristol-Myers-Squibb, Janssen, Merck, Novartis, Roche, Sanofi Genzyme, and Teva. VML has received consulting or speaking fees from: Almirall, Biogen, Genzyme, Janssen, Merck Serono, Novartis, Roche, Terumo, Sanofi, Teva, Celgene, and Bristol-Myers-Squibb. JPM has received speaker and consultation fees and congress travel support from: Biogen, Bristol-Myers-Squibb, Janssen, Merck, Novartis, Roche, and Sanofi. ARA has participated as a medical adviser/speaker for: Merck, Biogen, Novartis, Roche, Sanofi, Sandoz, Teva, and Bristol-Myers-Squibb. JMPG has been a consultant for Bayer Pharmaceuticals, Biogen Spain S.L., Daiichi Sankyo Spain, Genzyme Corporation, Janssen Spain, Merck Serono, Novartis Pharmaceuticals Corporation, Sanofi, Sandoz Iberia, Teva Pharmaceutical Industries, Roche Pharma, Almirall Prodesfarma S.A., and Celgene Spain S.L. He has participated as a speaker/moderator in meetings and/or symposiums organized by Almirall Prodesfarma S.A., Bayer Pharmaceuticals, Biogen Spain S.L., Genzyme Corporation, Merck Serono, Novartis Pharmaceuticals Corporation, Sanofi, Teva Pharmaceutical Industries, and Roche Pharma. EAM has received speaker honoraria from: Roche, Novartis, Merck, Sanofi, and Biogen. IPM has received payment or honoraria for lectures, presentations, speaker’s bureaus, manuscript writing or educational events from: Novartis. DMSS has participated as a medical adviser/speaker for Biogen, Novartis, Sanofi, Almirall, Roche, Merck, and Bristol-Myers-Squibb. MAV and JMRB are Novartis employees. JR has received speaking honoraria and support for attending meetings and/or travel in advisory boards from: Biogen-Idec, Genzyme, Merck-Serono, Novartis, Teva, Roche, Janssen, and Sanofi-Aventis. IGE, JRA, VGQ, ALF, FCP, JAGM, CMF and NHV: no disclosures reported.